Extended adjuvant tamoxifen for breast cancer?a new era?
Mené sur 12 894 femmes atteintes d'un cancer du sein ER+ de stade précoce et ayant reçu pendant cinq ans un traitement au tamoxifène, cet essai de phase III évalue les effets d'une poursuite du traitement pendant cinq ans sur le risque de récidive et la mortalité
Tamoxifen has been shown to reduce the risk of relapse and mortality in randomised trials of women with operable oestrogen receptor (ER)-positive breast cancer, with treatment for 5 years showing greater effectiveness than treatment for 2 years. However, results of trials assessing tamoxifen treatment for more than 5 years have been inconclusive. To address this uncertainty, Christina Davies and colleagues started the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, which included sub ...
The Lancet , commentaire, 2011